The antiplatelet agent ticlopidine is associated with the rapid onset of a thrombotic microangiopathy (TMA) resembling thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (aHUS). These disorders occur in 0.06% of individuals exposed to ticlopidine, usually within 1.5 to 6 weeks of exposure.1,2 The vast majority of ticlopidine TMsAs are accompanied by antibody-mediated inhibition of the protease ADAMTS13, making them similar to idiopathic TTP.3,4 However, ADAMTS13 deficiency alone is not sufficient for the development of TMsAs. Our group has shown that exposure to both the pharmacologic levels of ticlopidine and plasma from patients with ticlopidine TMsAs induces apoptosis in primary human microvascular endothelial cells, suggesting that ticlopidine-induced endothelial cell apoptosis is a provoking factor in ticlopidine TMsAs.5 In other TMsAs such as aHUS, complement regulatory protein mutations represent another provoking factor for the development of these diseases.6 Complement mutations have not been studied in ticlopidine TMsAs.

We obtained plasma samples from 4 consecutive patients with TMsAs that occurred within 2.5 to 4 weeks of ticlopidine exposure (Table 1).7 ADAMTS13 activity and inhibitor titers were determined, as previously described by Bennett et al.8 All patients had thrombocytopenia, schistocytosis, markedly elevated levels of lactate dehydrogenase (LDH), renal impairment, and significantly decreased ADAMTS13 activity. Three of 4 had ADAMTS13 inhibitors. Plasma levels of C5a and C5b-9 (membrane attack complex) were measured by enzyme-linked immunosorbent assay

Table 1. Clinical characteristics of 4 patients with ticlopidine TMsAs

<table>
<thead>
<tr>
<th>Patient code</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Duration of ticlopidine (wk)</th>
<th>Creatinine (μmol/L)</th>
<th>Platelets pretherapy</th>
<th>Platelets postrtherapy</th>
<th>LDH pretherapy (U/L)</th>
<th>LDH posttherapy (U/L)</th>
<th>Outcome</th>
<th>PEX sessions (N)</th>
<th>ADAMTS13 Activity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>010</td>
<td>84</td>
<td>M</td>
<td>3</td>
<td>110</td>
<td>40</td>
<td>235</td>
<td>2555</td>
<td>NA</td>
<td>Death</td>
<td>8</td>
<td>&lt;5</td>
</tr>
<tr>
<td>022</td>
<td>77</td>
<td>M</td>
<td>4</td>
<td>150</td>
<td>5</td>
<td>131</td>
<td>1084</td>
<td>214</td>
<td>Survival</td>
<td>10</td>
<td>&lt;5</td>
</tr>
<tr>
<td>003</td>
<td>78</td>
<td>F</td>
<td>3.5</td>
<td>260</td>
<td>33</td>
<td>93</td>
<td>1005</td>
<td>1736</td>
<td>Death</td>
<td>3</td>
<td>&lt;5</td>
</tr>
<tr>
<td>012</td>
<td>42</td>
<td>F</td>
<td>2.5</td>
<td>110</td>
<td>13</td>
<td>323</td>
<td>790</td>
<td>170</td>
<td>Survival</td>
<td>30</td>
<td>&lt;5</td>
</tr>
</tbody>
</table>

Platelet values expressed as ×10^11. | F, female; M, male; NA, not available; PEX, plasma exchange. | ADAMTS13 was assessed by both FRET-VWF assay (<5%) and immunoblot activity (<10%).
Table 2. Complement levels of 4 patients with ticlopidine TMAs and corresponding mutations

<table>
<thead>
<tr>
<th>Patient</th>
<th>CsA (ng/mL) (normal range, 0.3-70)</th>
<th>sC5b-9 (ng/mL) (normal range, 100-300)</th>
<th>CFH polymorphism</th>
</tr>
</thead>
<tbody>
<tr>
<td>010</td>
<td>32.08</td>
<td>4862</td>
<td>Homozygous exon</td>
</tr>
<tr>
<td>022</td>
<td>51.21</td>
<td>6023</td>
<td>Heterozygous exon</td>
</tr>
<tr>
<td>003</td>
<td>27.74</td>
<td>5904</td>
<td>Heterozygous exon</td>
</tr>
<tr>
<td>012</td>
<td>50.96</td>
<td>6229</td>
<td>Heterozygous exon</td>
</tr>
</tbody>
</table>

Priming used are exon 18 first step TAGACACAGACACACGAGG (forward), GTTACATCTCTTTTGAACTGGAAG (reverse); exon 18 second step AAATGTAGGATGTGAAGGC (forward), GTTACACCTACACTTTG AATGAAG (reverse), GGTACCACTTACACTTTGAAATGAAGA (reverse); exon 19 first step GTGTGAATCTCATTGCTACGGCT (forward), GGCTGGGCCACACATTA (reverse); and exon 19 second step ACAAAATGTGCTATATATTTCCTCAAG (forward), GGCTGGGCCACACATTA (reverse).

CFH, complement factor H.

(Quidel). Genomic DNA was isolated from plasma using the QIAamp kit (Qiagen). To determine the presence of complement mutations, we selected primers to soluble complement factor H (CFH), complement factor I, and membrane-linked membrane cofactor protein, 3 complement regulatory factors with mutations that have been identified with high frequency in aHUS.4,5 We found substantially elevated levels of membrane attack complex despite normal CsA levels, and all 4 patients had CFH genetic abnormalities (Table 2). Two of the 3 polymorphisms are of known functional significance, and even heterozygous CFH mutations are sufficient to develop aHUS.7,9

This is the first report of CFH mutations in ticlopidine TMAs. These mutations are otherwise uncommon in healthy individuals and have a background mutation rate of <5% in northern Europeans.10,11 ADAMTS13 deficiency has previously been considered to be pathognomonic of TTP. However, complement regulatory factor mutations represent another independent susceptibility factor in many types of TMAs, and their presence in addition to ADAMTS13 deficiency may be required for the onset of disease. If a complement mutation is required for TMA development after ticlopidine exposure, it could explain the rarity of ticlopidine TMAs despite the fact that the drug causes microvascular endothelial cell injury in vitro.5 Unlike idiopathic TTP, both aHUS and ticlopidine TMAs respond poorly to plasma exchange, even though hematologic parameters may normalize. Renal disease and overall mortality are not affected, and LDH levels do not return to normal, which suggests ongoing endothelial injury.9 We hypothesize that ticlopidine TMAs occur as a result of a failure to regulate complement on endothelial cell surfaces after cell injury, leading to ongoing microvascular damage. This defect may be present in other TMAs. We recently illustrated the role of complement in a patient with severe refractory idiopathic TTP with ADAMTS13 <5% and a high inhibitor titer. He rapidly responded to anti-C5 therapy after other treatment failures.12 No complement mutations were detected utilizing a commercially available platform. Subsequent analysis, however, did reveal a CFH mutation (unpublished data).12 In conclusion, complement regulatory protein mutations may form the basis for TMA susceptibility and should be further studied.

John Chapin
Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY

Stephen Eyler
Carver College of Medicine, University of Iowa, Iowa City, IA

Richard Smith
Carver College of Medicine, University of Iowa, Iowa City, IA

Han-Mou Tsai
Pennsylvania State University, University Park, PA

Jeffrey Laurence
Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY

Contribution: J.C. performed DNA extraction and collected clinical information; H.-M.T. performed ADAMTS13 testing; S.E. and R.S. performed semi-nested PCR on all DNA samples; J.L. and J.C. analyzed the data and authored the manuscript; and all authors contributed equally to the editing and revision of this work.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

H.-M.T. is not currently affiliated with any institution.

Correspondence: John Chapin, Division of Hematology-Oncology Payson 3, Weill Cornell Medical College, 525 E 68th St, New York, NY 10065; e-mail: joc9160@nyhp.org.

References


11. Jönsson A, Nilsson SC, Ahlqvist E, et al. Mutations in genes encoding complement regulatory factor mutations as independent susceptibility factor in many types of TMAs, and their presence in addition to ADAMTS13 deficiency may be required for the onset of disease. If a complement mutation is required for TMA development after ticlopidine exposure, it could explain the rarity of ticlopidine TMAs despite the fact that the drug causes microvascular endothelial cell injury. Unlike idiopathic TTP, both aHUS and ticlopidine TMAs respond poorly to plasma exchange, even though hematologic parameters may normalize. Renal disease and overall mortality are not affected, and LDH levels do not return to normal, which suggests ongoing endothelial injury. We hypothesize that ticlopidine TMAs occur as a result of a failure to regulate complement on endothelial cell surfaces after cell injury, leading to ongoing microvascular damage. This defect may be present in other TMAs. We recently illustrated the role of complement in a patient with severe refractory idiopathic TTP with ADAMTS13 <5% and a high inhibitor titer. He rapidly responded to anti-C5 therapy after other treatment failures. No complement mutations were detected utilizing a commercially available platform. Subsequent analysis, however, did reveal a CFH mutation (unpublished data). In conclusion, complement regulatory protein mutations may form the basis for TMA susceptibility and should be further studied.

John Chapin
Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY
Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies

John Chapin, Stephen Eyler, Richard Smith, Han-Mou Tsai and Jeffrey Laurence